Booth Bruce 4/A
4/A · Kymera Therapeutics, Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) Director Booth Bruce Sells Shares
What Happened
Booth Bruce (listed as a Director) reported multiple sales of Kymera Therapeutics (KYMR) common stock on June 29, 2026. The filing shows aggregate disposals of 76,650 shares across several trades at reported weighted-average prices, generating roughly $8.28 million in proceeds. These transactions are coded as sales (S) — routine disposals rather than purchases or option exercises.
Key Details
- Filing date: July 2, 2026 (Amended Form 4). Period of report: June 26, 2026. Transactions dated June 29, 2026.
- Aggregate shares sold: 76,650; aggregate proceeds: ≈ $8,281,903.
- Reported prices: weighted-average prices per reported lot; overall trade prices ranged roughly from $105.02 to $111.63 per share (sales executed in multiple transactions).
- Relevant footnotes: sales were executed pursuant to a Rule 10b5-1 plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. (F1). The filing was amended to correct the allocation of reported sales between Atlas Venture Fund X and Atlas Venture Opportunity Fund I; the aggregate sold amount is unchanged. Reporting person disclaims Section 16 beneficial ownership of shares held by those funds except to the extent of any pecuniary interest (F11). The filing notes weighted-average pricing and offers to provide detailed breakdowns of trades/prices on request (F3, F5–F10).
- Shares owned after transaction: not specified in the summary data provided here (original filing had an inadvertent misreport which this amendment corrects — F2).
- Transaction code: S = Sale. This is an amendment to the original Form 4 (not a new late-report flag in the supplied data).
Context
These sales appear to be institutional dispositions by Atlas Venture-affiliated funds (Atlas Venture Fund X and Atlas Venture Opportunity Fund I) under a pre-established 10b5-1 plan rather than a personal, spontaneous trade by an individual executive. The reporting structure indicates the listed reporting person is a member of the general partner entities and disclaims direct Section 16 beneficial ownership of the funds’ holdings, except for any pecuniary interest. Institutional or planned sales are common and do not, by themselves, indicate management’s view on company fundamentals. For full details (exact post-sale holdings or the per-price breakdown of each sub-trade), consult the amended Form 4 filing (Accession: 0001451612-26-000022).
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3][F4]2026-06-29$105.78/sh−5,549$586,973→ 2,446,375 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F5][F4]2026-06-29$106.63/sh−14,798$1,577,911→ 2,431,577 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F6][F4]2026-06-29$107.76/sh−19,419$2,092,591→ 2,412,158 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F7][F4]2026-06-29$108.28/sh−10,848$1,174,621→ 2,401,310 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F8][F4]2026-06-29$109.75/sh−7,968$874,488→ 2,393,342 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F9][F4]2026-06-29$110.67/sh−7,723$854,704→ 2,385,619 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F10][F4]2026-06-29$111.20/sh−934$103,861→ 2,384,685 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F3][F11]2026-06-29$105.78/sh−770$81,451→ 471,497 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F5][F11]2026-06-29$106.63/sh−2,133$227,442→ 469,364 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F6][F11]2026-06-29$107.76/sh−2,698$290,736→ 466,666 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F7][F11]2026-06-29$108.28/sh−1,498$162,203→ 465,168 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F8][F11]2026-06-29$109.75/sh−1,104$121,164→ 464,064 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F9][F11]2026-06-29$110.67/sh−1,078$119,302→ 462,986 total(indirect: See footnote) - Sale
Common Stock
[F1][F2][F10][F11]2026-06-29$111.20/sh−130$14,456→ 462,856 total(indirect: See footnote)
Footnotes (11)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive.
- [F11]The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any.
- [F2]The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10).
- [F4]These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive.